Related Experiment Video

Updated: Mar 27, 2026

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
06:54

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

14.8K

Serum deprivation response inhibits breast cancer progression by blocking transforming growth factor-β signaling

Yao Tian1,2,3, Yue Yu1,2,3, Li-Kun Hou1,2,3

  • 1The First Department of Breast Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, China.

Cancer Science
|January 11, 2016
PubMed

Insights

Serum deprivation response (SDPR) inhibits breast cancer progression by suppressing cell proliferation and invasion. SDPR downregulation activates transforming growth factor-β (TGF-β) signaling, promoting epithelial-mesenchymal transition and cancer advancement.

Area of Science:

  • Molecular Biology
  • Cancer Research
  • Cell Biology

Background:

  • Serum deprivation response (SDPR) is involved in membrane dynamics and caveolae formation.
  • The role of SDPR in cancer, particularly breast cancer, remains largely undefined.

Purpose of the Study:

  • To investigate the function of SDPR in breast cancer development and progression.
  • To elucidate the molecular mechanisms underlying SDPR's role in cancer.

Main Methods:

  • Analysis of SDPR expression in human breast cancer tissues.
  • Overexpression and depletion studies in breast cancer cell lines (MDA-MB-231) and normal breast epithelial cells (MCF10A).
  • Assessment of cell proliferation, invasion, epithelial-mesenchymal transition (EMT) markers, and transforming growth factor-β (TGF-β) signaling pathway activation.

Main Results:

  • SDPR expression is downregulated in human breast cancer.
  • Overexpression of SDPR inhibited proliferation and invasion in MDA-MB-231 cells.
  • Depletion of SDPR promoted proliferation and invasion in MCF10A cells, inducing an EMT-like phenotype.
  • SDPR depletion led to the activation of TGF-β signaling via upregulation of TGF-β1.

Conclusions:

  • SDPR acts as a tumor suppressor in breast cancer.
  • SDPR inhibits breast cancer progression by suppressing cell proliferation and invasion.
  • SDPR blocks TGF-β signaling, thereby preventing EMT and cancer advancement.
Keywords:
Breast cancerepithelial-mesenchymal transitionprogressionserum deprivation responsetransforming growth factor-β

More Related Videos

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

2.5K
Spheroid Assay to Measure TGF-β-induced Invasion09:18

Spheroid Assay to Measure TGF-β-induced Invasion

Published on: November 16, 2011

22.6K

Related Concept Videos

TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
10.9K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.2K
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

5.6K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.7K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.4K